乳腺癌分子显像研究进展

胡鸿; 唐刚华; 聂大红; 胡鸿; 唐刚华; 聂大红

doi:10.3760/cma.j.issn.1673-4114.2015.01.019

[1]

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30. doi: 10.3322/caac.21166

[2]

陈武飞, 刘海泉, 滑炎卿.乳腺癌影像学诊断研究进展[J].中华临床医师杂志:电子版, 2013, 7(11):123-125.

[3]

刘芳, 唐光才.乳腺癌影像诊断的研究现状[J].国际医学放射学杂志, 2013, 36(6):533-537. doi: 10.3874/j.issn.1674-1897.2013.06.Z0605

[4]

李丽艳, 周顺科, 孙划.乳腺癌影像学诊断新进展[J].中国临床研究, 2013, 26(7):724-725.

[5]

Thomassin-Naggara I, De Bazelaire C, Chopier J, et al. Diffusion-weighted MR imaging of the breast:advantages and pitfalls[J]. Eur J Radiol, 2013, 82(3):435-443.

[6]

Magometschnigg HF, Helbich T, Brader P, et al. Molecular imaging for the characterization of breast tumors[J]. Expert Rev Anticancer Ther, 2014, 14(6):711-722. doi: 10.1586/14737140.2014.885383

[7]

Pinker K, Bogner W, Baltzer P, et al. Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7 T[J]. Eur Radiol, 2014, 24(4):913-920.

[8]

Bains LJ, Zweifel M, Thoeny HC. Therapy response with diffusion MRI:an update[J]. Cancer Imaging, 2012, 12(2):395-402. doi: 10.1102/1470-7330.2012.9047

[9]

邓丹琼, 涂蓉, 尤小光, 等.磁共振扩散加权成像ADC值与乳腺癌病理组织分级的相关性研究[J].临床放射学杂志, 2013, 32(10):1428-1431.

[10]

Baltzer PA, Dietzel M. Breast lesions:diagnosis by using proton MR spectroscopy at 1. 5 and 3. 0 T-systematic review and meta-analysis[J]. Radiology, 2013, 267(3):735-746.

[11]

Pinker K, Helbich TH, Magometschnigg H, et al. Molekulare Brustbildgebung. Ein Update[J]. Radiologe, 2014, 54(3):241-253. doi: 10.1007/s00117-013-2580-8

[12]

Pinker K, Bickel H, Helbich TH, et al. Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the "Breast Imaging Reporting and Data System" for multiparametric 3-T imaging of breast lesions[J]. Eur Radiol, 2013, 23(7):1791-1802.

[13]

Fowler AM. A molecular approach to breast imaging[J]. J Nucl Med, 2014, 55(2):177-180.

[14]

Bensch F, Kruchten M, Lamberts L, et al. Molecular imaging for monitoring treatment response in breast cancer patients[J]. Eur J Pharmacol, 2013, 717(1-3):2-11. doi: 10.1016/j.ejphar.2013.01.079

[15]

Kenny LM, Al-Nahhas A, Aboagye EO. Novel PET biomarkers for breast cancer imaging[J]. Nucl Med Commun, 2011, 32(5):333-335.

[16]

黄婷婷, 王红亮, 唐刚华.细胞凋亡小分子PET显像剂的研究进展[J].同位素, 2011, 24(4):240-245.

[17]

Cheng J, Lei L, Xu J, et al. ¹⁸F-fluoromisonidazole PET/CT:a potential tool for predicting primary endocrine therapy resistance in breast cancer[J]. J Nucl Med, 2013, 54(3):333-340.

[18]

van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer[J]. Lancet Oncol, 2013, 14(11):e465-e475. doi: 10.1016/S1470-2045(13)70292-4

[19]

Gemignani1 ML, Patil S, Seshan VE, et al. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer[J]. J Nucl Med, 2013, 54(10):1697-1702. doi: 10.2967/jnumed.112.113373

[20]

Gaykema SB, Brouwers AH, Hovenga S, et al. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer[J]. J Clin Oncol, 2012, 30(6):e74-e75.

[21]

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positivve advanced breast cancer[J]. N Engl J Med, 2012, 367(19):1783-1791. doi: 10.1056/NEJMoa1209124

[22]

Tamura K, Kurihara H, Yonemori K, et al. ⁶⁴Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer[J]. J Nucl Med, 2013, 54(11):1869-1875. doi: 10.2967/jnumed.112.118612

[23]

Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors[J]. Nat Biotechnol, 2004, 22(6):701-706. doi: 10.1038/nbt968

[24]

胡鸿, 唐刚华, 胡孔珍.肿瘤酸性pH分子显像研究进展[J].同位素, 2014, 27(3):179-187.

[25]

董佳佳, 章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志, 2014, 38(6):427-432.